Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells

References

• Terry KL, Schock H, Fortner Y, Husing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22:4664–4675.
   PubMed Web of Science ®Google Scholar
• Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers. 2007;23:397–410.10.1155/2007/309382
   PubMed Web of Science ®Google Scholar
• Thedrez A, Lavoue V, Dessarthe B, Daniel P, Henno S, Jaffre I, et al. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients. PLoS One. 2013;8:e63322.10.1371/journal.pone.0063322
   PubMed Web of Science ®Google Scholar
• Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857–65.10.2741/2805
   PubMed Web of Science ®Google Scholar
• Schmidt M, Lichtner RB. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat. 2002;5:11–8.10.1016/S1368-7646(02)00004-3
   PubMed Web of Science ®Google Scholar
• Ma SK, Joo SY, Choi HI, Bae EH, Nam KI, Lee J, et al. Activation of G-protein-coupled receptor 40 attenuates the cisplatin-induced apoptosis of human renal proximal tubule epithelial cells. Int J Mol Med. 2014;34:1117–23.
   PubMed Web of Science ®Google Scholar
• Hurst JH, Hooks SB. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol. 2009;78:1289–97.10.1016/j.bcp.2009.06.028
   PubMed Web of Science ®Google Scholar
• Lambert NA, Johnston CA, Cappell SD, Kuravi S, Kimple AJ, Willard FS, et al. Regulators of G-protein Signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity. Proc Nat Acad Sci. 2010;107:7066–71.10.1073/pnas.0912934107
   PubMed Web of Science ®Google Scholar
• Cacan E, Kratzer JT, Cole MF, Gaucher EA. Interchanging functionality among homologous elongation factors using signatures of heterotachy. J Mol Evol. 2013;76:4–12.10.1007/s00239-013-9540-9
   PubMed Web of Science ®Google Scholar
• Nance MR, Kreutz B, Tesmer VM, Sterne-Marr R, Kozasa T, Tesmer JJ. Structural and functional analysis of the regulator of G protein signaling 2-Gαq Complex. Structure. 2013;21:438–48.10.1016/j.str.2012.12.016
   PubMed Web of Science ®Google Scholar
• Wolff DW, Xie Y, Deng C, Gatalica Z, Yang M, Wang B, et al. Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer. 2012;130:1521–31.10.1002/ijc.v130.7
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Sinnarajah S. RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol. 2002;34:432–8.10.1016/S1357-2725(01)00141-8
   PubMed Web of Science ®Google Scholar
• Liang G, Bansal G, Xie Z, Druey KM. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem. 2009;284:21719–27.10.1074/jbc.M109.028407
   PubMed Web of Science ®Google Scholar
• Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, et al. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One. 2013;8:e60185.10.1371/journal.pone.0060185
   PubMed Web of Science ®Google Scholar
• Hurst JH, Mendpara N, Hooks SB. Regulator of G-protein signaling expression and function in ovarian cancer cell lines. Cell Mol Biol Lett. 2009;14:153–74.
   PubMed Web of Science ®Google Scholar
• Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One. 2014;9:e87455.10.1371/journal.pone.0087455
   PubMed Web of Science ®Google Scholar
• Cacan E. Histone deacetylase-1-mediated suppression of FAS in chemoresistant ovarian cancer cells. Anticancer Res. 2016;36:2819–26.
   PubMed Web of Science ®Google Scholar
• Cacan E, Greer SF, Garnett-Benson C. Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases. Int J Oncol. 2015;47:2264–75.
   PubMed Web of Science ®Google Scholar
• Morgan JE, Shanderson RL, Boyd NH, Cacan E, Greer SF. The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitination. Biosci Rep. 2015;35:e00233.
   Google Scholar
• Ying L, Lin J, Qiu F, Cao M, Chen H, Liu Z, et al. Epigenetic repression of regulator of G-protein signaling 2 by ubiquitin-like with PHD and ring-finger domain 1 promotes bladder cancer progression. FEBS J. 2015;282:174–82.10.1111/febs.13116
   PubMed Web of Science ®Google Scholar
• Lyu JH, Park DW, Huang B, Kang SH, Lee SJ, Lee C, et al. RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. J Cell Biochem. 2015;116:260–7.10.1002/jcb.24964
   PubMed Web of Science ®Google Scholar
• Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol. 2014;4:111.
   PubMedGoogle Scholar
• Kwon MJ, Shin YK. Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci. 2011;12:983–1008.10.3390/ijms12020983
   PubMed Web of Science ®Google Scholar
• Yu W, Jin C, Lou X, Han X, Li L, He Y, et al. Global analysis of DNA methylation by methyl-capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One. 2011;6:e29450.10.1371/journal.pone.0029450
   PubMed Web of Science ®Google Scholar
• Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, et al. Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 2010;90:414–25.10.1038/labinvest.2009.138
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28.10.2353/ajpath.2009.080874
   PubMed Web of Science ®Google Scholar
• Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol. 2008;19:185–90.10.3802/jgo.2008.19.3.185
   PubMedGoogle Scholar
• Pchejetski D, Alfraidi A, Sacco K, Alshaker H, Muhammad A, Monzon L. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer. J Cancer Res Clin Oncol. 2015;142:1659–1671.
   PubMed Web of Science ®Google Scholar
• Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets. 2013;17:29–41.10.1517/14728222.2013.729042
   PubMed Web of Science ®Google Scholar
• Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–41.10.3390/molecules20033898
   PubMed Web of Science ®Google Scholar
• Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97:1344–53.10.1038/sj.bjc.6604025
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21.10.1016/j.canlet.2008.08.016
   PubMed Web of Science ®Google Scholar
• Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med. 2012;4:1092–6.
   PubMed Web of Science ®Google Scholar
• Tian F, Yip SP, Kwong DL, Lin Z, Yang Z, Wu VW. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 2013;37:708–13.10.1016/j.canep.2013.05.012
   PubMed Web of Science ®Google Scholar
• Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009;2:34.10.1186/1755-8794-2-34
   PubMed Web of Science ®Google Scholar
• Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer. 2011;2:607–17.10.1177/1947601910393957
   PubMedGoogle Scholar
• Muller CI, Ruter B, Koeffler HP, Lubbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol. 2006;7:315–21.10.2174/138920106778521523
   PubMed Web of Science ®Google Scholar
• Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110:1923–9.10.1038/bjc.2014.116
   PubMed Web of Science ®Google Scholar
• Hooks SB, Callihan P, Altman MK, Hurst JH, Ali MW, Murph MM. Regulators of G-protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010;9:289.10.1186/1476-4598-9-289
   PubMed Web of Science ®Google Scholar